Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?

Marilynn Larkin  |  June 8, 2017

(Reuters Health)—A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn’t have dangerous side effects, researchers say.

Dr. Jean-Yves Reginster of Liege State University in Belgium and colleagues recruited 604 people over age 50 with knee osteoarthritis (OA) from five European countries and randomly assigned them to take 800 mg extra-pure chondroitin sulfate (Chondrosulf), 200 mg celecoxib or a placebo every day for six months.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Those who took chondroitin sulfate or celecoxib had similar levels of pain relief at the end of the study, and in both groups the improvement was greater than for those taking just a placebo, according to the report May 22 online in Annals of the Rheumatic Diseases.1

Reginster tells Reuters Health the findings are in line with earlier studies showing pharmaceutical-grade chondroitin sulfate could significantly decrease the progression of knee OA over a period of three years.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He stressed that pharmaceutical-grade chondroitin is not the same as over-the-counter supplements, which are made differently and can’t get into the joint in high enough concentrations to combat the causes of cartilage degradation and pain.

European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate, as well as pharmaceutical-grade glucosamine sulfate, as first-line treatments for OA, Reginster says by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs), including stomach ulcers, bleeding, liver and kidney problems.

Dr. Michael Shepard of Hoag Orthopedic Institute in Orange, Calif., noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.

In addition, U.S.-based studies of chondroitin have had mixed results, says Shepard, who wasn’t involved in the study. Some have found the supplements to be as effective as ibuprofen (also an NSAID), and some have found that chondroitin sulfate is no more effective than placebo, he tells Reuters Health.

“I tell my patients, ‘buyer beware,’” Dr. Shepard say. “I tell them about the mixed results of chondroitin in the literature. I tell them to try chondroitin for one month as a trial and if they like it and feel better with it, then keep taking it.”

If chondroitin doesn’t work for them, he suggests taking an NSAID periodically, and to be aware of the side effects.

“If you are going to stay on an NSAID for a prolonged period then you need regular follow up with your doctor,” Shepard cautions.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:chondroitin sulfateKnee Osteoarthritis (OA)knee painnonsteroidal antiinflammatory drug (NSAID)NSAIDsPain

Related Articles

    Osteoarthritis Quo Vadis

    March 1, 2008

    Our knowledge of OA has progressed far—does a cure lie ahead?

    Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

    August 24, 2016

    (Reuters Health)—Glucosamine sulfate and chondroitin sulfate are not more beneficial than placebo treatments for patients with knee osteoarthritis, a recent trial suggests. In a double-blind study, researchers investigated the efficacy of a medicine that delivered both glucosamine and chondroitin sulfate. The 164 participants all had osteoarthritis and moderate to severe knee pain. ad goes here:advert-1ADVERTISEMENTSCROLL…

    How to Discuss Anti-Inflammatory Diets & Supplements with Your Patients

    June 9, 2023

    My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…

    Celecoxib Is a Safe Treatment for Arthritis

    February 20, 2017

    A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences